newsfilter
← Latest News
PR Newswire·

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

  • Azitra CEO Francisco Salva issued a shareholder letter outlining strategic growth initiatives & an outlook for 2026 & beyond.
  • The company reoriented its strategy in the first half of 2026 to prioritize programs with near-term value-creating milestones.
  • A March 2026 financing raised $10.5 million plus up to $21 million through warrant exercises to fund expansion.
  • Azitra is launching ATR-COSF, a recombinant filaggrin protein program for the cosmetic market targeting fine lines & wrinkles.
  • ATR-COSF clinical studies to evaluate effects on fine lines & wrinkles are expected to complete in late 2026 for potential 2027 commercialization.
  • The company is expanding into biotechnology products using in-licensed microbial genetic engineering technologies from The Fred Hutchinson Cancer Center.
  • Initial biotech initiatives focus on developing mRNA-related assembly proteins, specifically Tobacco Etch Virus (TEV) Protease & T7 RNA Polymerase.
  • These recombinant protein programs target a market estimated at approximately $1 billion & aim for partnership or commercialization within 36 months.
  • ATR-04 enrollment for EGFR inhibitor-associated rash continues with the addition of MD Anderson Cancer Center as a clinical site.
  • Azitra plans to pause enrollment in the ATR-12 Netherton syndrome trial to conserve capital & redirect funds to ATR-COSF.
  • The company intends to restart ATR-12 work in the future using improved topical formulations & next-generation candidates.
  • Azitra leverages synthetic biology, artificial intelligence, & microbial genetic engineering to create value across dermatology, cosmetics, & biotech sectors.